[go: up one dir, main page]

WO2013009143A3 - Marqueur pour le diagnostic d'une rétinopathie diabétique - Google Patents

Marqueur pour le diagnostic d'une rétinopathie diabétique Download PDF

Info

Publication number
WO2013009143A3
WO2013009143A3 PCT/KR2012/005622 KR2012005622W WO2013009143A3 WO 2013009143 A3 WO2013009143 A3 WO 2013009143A3 KR 2012005622 W KR2012005622 W KR 2012005622W WO 2013009143 A3 WO2013009143 A3 WO 2013009143A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic retinopathy
diagnosing diabetic
marker
diagnosing
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/005622
Other languages
English (en)
Korean (ko)
Other versions
WO2013009143A2 (fr
WO2013009143A9 (fr
Inventor
김영수
유형곤
김경곤
김상진
유지영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Publication of WO2013009143A2 publication Critical patent/WO2013009143A2/fr
Publication of WO2013009143A9 publication Critical patent/WO2013009143A9/fr
Publication of WO2013009143A3 publication Critical patent/WO2013009143A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une composition et une trousse comprenant un agent pour la mesure d'un niveau d'un gène ou d'une protéine qui peuvent être utilisés pour diagnostiquer et déterminer la progression d'un patient atteint d'une rétinopathie diabétique, pour le diagnostic d'une rétinopathie diabétique, un procédé pour fournir des informations pour le diagnostic d'une rétinopathie diabétique, et une méthode de diagnostic d'une rétinopathie diabétique à l'aide de la composition et de la trousse.
PCT/KR2012/005622 2011-07-14 2012-07-13 Marqueur pour le diagnostic d'une rétinopathie diabétique Ceased WO2013009143A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0070122 2011-07-14
KR1020110070122A KR20130009204A (ko) 2011-07-14 2011-07-14 당뇨망막병증 진단용 마커 및 이의 용도

Publications (3)

Publication Number Publication Date
WO2013009143A2 WO2013009143A2 (fr) 2013-01-17
WO2013009143A9 WO2013009143A9 (fr) 2013-03-28
WO2013009143A3 true WO2013009143A3 (fr) 2013-05-30

Family

ID=47506750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/005622 Ceased WO2013009143A2 (fr) 2011-07-14 2012-07-13 Marqueur pour le diagnostic d'une rétinopathie diabétique

Country Status (2)

Country Link
KR (1) KR20130009204A (fr)
WO (1) WO2013009143A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020179953A1 (fr) * 2019-03-07 2020-09-10 (주)레티마크 Marqueur composite radioactif pour le diagnostic d'un mélanome malin et utilisation de ce dernier
US20220146531A1 (en) * 2019-03-07 2022-05-12 Reti Mark Co., Ltd. A combination of biomarkers for diagnosing of diabetic retinopathy and use thereof
WO2020189821A1 (fr) * 2019-03-20 2020-09-24 (주)레티마크 Marqueur sanguin pour diagnostiquer les principales maladies responsables de cécité, et procédé de diagnostic les utilisant
RU2765437C1 (ru) * 2021-08-17 2022-01-31 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ определения уровня экспрессии гена, кодирующего PEDF, в тканях глаза кролика Oryctolagus cuniculus и набор для его определения

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEN-BO GAO ET AL., JOURNAL OFPROTEOME RESEARCH., vol. 7, no. 6, 24 April 2008 (2008-04-24), pages 2516 - 2525 *
KIM, GYEONG GON., THESIS FOR DOCTORATE IN SEOUL UNIVERSITY., 2010 *
KYUNGGON KIM ET AL., JOURNAL OFPROTEOME RESEARCH., vol. 9, no. 2, 18 December 2009 (2009-12-18), pages 689 - 699 *

Also Published As

Publication number Publication date
WO2013009143A2 (fr) 2013-01-17
WO2013009143A9 (fr) 2013-03-28
KR20130009204A (ko) 2013-01-23

Similar Documents

Publication Publication Date Title
WO2013009146A3 (fr) Marqueur pour le diagnostic d'une rétinopathie diabétique
WO2009085234A3 (fr) Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
HK1210831A1 (en) Compositions and methods for detecting protease activity in biological systems
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
EA201590027A1 (ru) Способы детекции заболеваний или состояний
WO2012021407A3 (fr) Biomarqueurs pour accident vasculaire cérébral
WO2013163568A3 (fr) Procédés d'évaluation du statut de cancer du poumon
WO2013153461A3 (fr) Biomarqueurs salivaires spécifiques pour la détection de risques, le diagnostic précoce, le pronostic et la surveillance de la maladie d'alzheimer et de la maladie de parkinson
WO2013066764A3 (fr) Marqueurs de signature de la maladie d'alzheimer et procédés d'utilisation
WO2010136163A8 (fr) Sécernine-1, en tant que marqueur du cancer
ATE554389T1 (de) Apex als marker für lungenkrebs
WO2009149319A3 (fr) Profils d’expression de gène associés à des crises d’exacerbation d’asthme
WO2011156734A3 (fr) Procédé de caractérisation de maladies vasculaires
WO2013049152A3 (fr) Procédés pour évaluer le statut du cancer du poumon
WO2012107841A3 (fr) Marqueurs biologiques de micro-arn et procédés pour les utiliser
WO2010097186A8 (fr) Utilisation de s-erbb-3 comme marqueur des cancers
WO2011143574A3 (fr) Marqueurs biologiques plasmatiques pour le diagnostic de la maladie d'alzheimer
WO2010046648A3 (fr) Essai diagnostique pour streptococcus equi
WO2014043633A8 (fr) Utilisation de e-cadhérine et de vimentine pour la sélection de patients répondant à un traitement
EP3285071A4 (fr) Composition de biomarqueur pour le diagnostic de la maladie de still, trousse de diagnostic et procédé de diagnostic
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
WO2013009143A3 (fr) Marqueur pour le diagnostic d'une rétinopathie diabétique
WO2012049225A3 (fr) Séquences de marqueur pour lupus érythémateux systémique et leurs utilisations
WO2015069883A8 (fr) Fraction oxydée de l'adn extracellulaire utilisable en tant que biomarqueur du stress et ses procédés d'utilisation
WO2012081007A3 (fr) Procédés de diagnostic et de traitement du cancer du pancréas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12810761

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12810761

Country of ref document: EP

Kind code of ref document: A2